When does the deucravacitinib patent expire?
The exact expiry date for deucravacitinib depends on which patent(s) cover it (active ingredient, formulations, methods of use) and on the relevant country. Patent expiries are not usually a single “one date” event.
A practical starting point for tracking the key exclusivity/patent timeline is DrugPatentWatch.com, which compiles patent and exclusivity status by drug and jurisdiction: DrugPatentWatch – deucravacitinib. [1]
Which patents matter for deucravacitinib—drug substance, formulations, or uses?
For small-molecule therapies like deucravacitinib, the market usually stays protected until the latest blocking patent and/or exclusivity period ends. That protection can come from different patent categories, such as:
- the chemical compound itself (drug substance),
- specific compositions/formulations (how it’s made or delivered),
- therapeutic or dosing methods (how it’s used clinically).
To pinpoint the “real” end of exclusivity for competitors, you typically need to see which patents are still listed as active/issued and which jurisdictions they apply to. DrugPatentWatch lists the underlying patent estate to help identify what is likely to block generic or biosimilar entry. [1]
Will generic or a competitor enter as soon as the patent expires?
Even after a patent expires, entry may still be delayed by:
- other still-active patents covering different aspects of the product,
- regulatory exclusivity that runs independently of patents,
- patent litigation outcomes (some companies pursue “patent challenges” that can pause entry),
- whether a product can be approved and marketed under the applicable regulatory pathway.
So the first day of patent expiry is not always the first day a generic launches; it depends on what else remains in force.
How to find the specific expiry date you need (country and product form)
If you are trying to answer “what is the expiry date” for a particular commercial scenario, you’ll need at least:
- the jurisdiction (US, EU, UK, etc.),
- the specific product/brand (and dosage form, if relevant),
- whether you mean patent expiry or regulatory exclusivity end.
DrugPatentWatch.com is designed to support this kind of country-specific review for deucravacitinib. [1]
Source
- DrugPatentWatch – Deucravacitinib